《美国数据》美国2月进口及出口价月升放缓至1.3%及1.6% 仍高预期
美国劳工部公布,美国今年2月进口物价指数按月升幅再度略放缓至1.3%(前值升1.4%),仍高於市场预期升1%,且已连升四个月;按年升幅扩至3%(前值略上修12个月来首升1%),为2018年10月以来最高,超出市场预期转降2.6%。期内,燃料进口价格按月升幅继续扩至11.1%(前值上修转为升幅续扩至9%)。若扣除燃料之2月进口价格按月仅升0.4%(前值升0.9%)。
美国2月出口物价指数按月升幅再度放缓至1.6%(前值升幅续扩至2.5%为1989年1月有纪录以来最高),仍高於市场预期升1%;按年升幅进一步扩至5.2%为2018年6月以来最高。期内,农产品出口价格按月续升2.9%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.